Spanish drugmaker Almirall has extended its relationship with Quintiles, tabbing the CRO to promote its respiratory portfolio and new COPD drug in the U.K. The drug got its European approval last week, and the partnership follows Quintiles' work in clinical trials for the treatment. Neither company disclosed the terms of the deal. Release